<p>Annexon（纳斯达克股票代码：ANNX - 获取免费报告）在周二发布的报告中被高盛集团的研究分析师上调至 “持有” 评级，Zacks.com 报道。</p>
<p>其他一些股票分析师最近也对 ANNX 发布了报告。Chardan Capital 在 3 月 20 日的研究报告中重申了对 Annexon 的 “买入” 评级，并设定了 16.00 美元的目标价。Cantor Fitzgerald 在 1 月 14 日的报告中重申了对 Annexon 的 “增持” 评级。Weiss Ratings 在 4 月 20 日的报告中重申了对 Annexon 的 “卖出（d-）” 评级。最后，Wall Street Zen 在周六的报告中将 Annexon 的评级从 “卖出” 上调至 “持有”。四位分析师给予该股票 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Annexon 的平均评级为 “持有”，平均目标价为 16.00 美元。</p>
<p><strong>阅读我们关于 Annexon 的最新研究报告</strong></p>
<h2>Annexon 价格表现</h2>
<p>ANNX 股票在周二开盘价为 5.44 美元。该公司的市值为 8.9129 亿美元，市盈率为-4.46，贝塔值为 1.22。公司的 50 日简单移动平均线为 5.70 美元，200 日简单移动平均线为 5.14 美元。Annexon 的年低为 1.67 美元，年高为 7.18 美元。</p>
<p>Annexon（纳斯达克股票代码：ANNX - 获取免费报告）最近在 5 月 7 日发布了其财报。该公司报告季度每股收益（EPS）为-0.23 美元，超出分析师一致预期的-0.30 美元，超出幅度为 0.07 美元。研究分析师平均预计 Annexon 在当前财年将发布-1.05 美元的每股收益。</p>
<h2>Annexon 内部活动</h2>
<p>在其他消息中，首席财务官 Jennifer Lew 在 2 月 18 日的交易中出售了 7,851 股 Annexon 股票。这些股票以平均价格 5.11 美元出售，总价值为 40,118.61 美元。出售后，首席财务官持有公司 113,765 股股票，价值 581,339.15 美元。这笔交易代表其持股比例减少了 6.46%。该出售在向证券交易委员会提交的文件中披露，文件可通过此链接获取。此外，执行副总裁 Michael Overdorf 在 2 月 18 日的交易中出售了 6,225 股 Annexon 股票。这些股票以平均价格 5.10 美元出售，总交易额为 31,747.50 美元。出售完成后，该执行副总裁持有公司 124,464 股股票，价值约 634,766.40 美元。这笔交易代表其持股比例减少了 4.76%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在上个季度出售了 32,513 股公司股票，价值 165,973 美元。目前，内部人士持有该股票的比例为 12.67%。</p>
<h2>对 Annexon 的对冲基金看法</h2>
<p>机构投资者和对冲基金最近买入和卖出了该公司的股票。Rhenman &amp; Partners Asset Management AB 在第三季度将其在 Annexon 的持股比例提高了 78.9%。Rhenman &amp; Partners Asset Management AB 目前拥有 823,000 股公司股票，价值 2,510,000 美元，此前在上个季度增持了 363,000 股。Caitong International Asset Management Co. Ltd 在第四季度购买了 Annexon 的新头寸，价值约 82,000 美元。DNB Asset Management AS 在第四季度将其在 Annexon 的持股比例提高了 40.0%。DNB Asset Management AS 目前拥有 118,324 股公司股票，价值 594,000 美元，此前增持了 33,801 股。CWM LLC 在第四季度将其在 Annexon 的持股比例提高了 29.0%。CWM LLC 目前拥有 30,297 股公司股票，价值 152,000 美元，此前增持了 6,809 股。最后，Mirae Asset Global Investments Co. Ltd.在第四季度将其在 Annexon 的持股比例提高了 65.6%。Mirae Asset Global Investments Co. Ltd.目前拥有 7,033 股公司股票，价值 35,000 美元，此前增持了 2,785 股。</p>
<h2>Annexon 的关键新闻</h2>
<p>以下是本周影响 Annexon 的关键新闻：</p>
<ul>
<li>积极情绪：HC Wainwright 提高了对 Annexon 多个时期的收益预期，包括 2026 财年、2027 财年、2028 财年和 2029 财年，显示出对公司长期收益轨迹的信心增强。</li>
<li>积极情绪：该公司还提高了 2026 年第二、第三和第四季度的每股收益预测，这可能有助于增强投资者对 Annexon 运营前景的信心。</li>
<li>中性情绪：独立市场数据显示空头头寸为零股，这在最新报告中似乎并不是一个重要的交易因素。</li>
<li>中性情绪：与格林 - 巴利综合症相关的意识月新闻稿也已发布，但未包含对 Annexon 的直接业务更新或临床催化剂。文章标题</li>
</ul>
<h2>Annexon 公司简介</h2>
<p>（获取免费报告）</p>
<p>Annexon Inc 是一家临床阶段的生物技术公司，专注于针对神经退行性和神经免疫疾病患者的补体靶向疗法的发现和开发。该公司的研究平台以抑制 C1 复合物为核心，C1 复合物是经典补体途径的关键启动因子，涉及多种罕见且危及生命的疾病。通过选择性靶向上游补体激活，Annexon 旨在防止特征性疾病（如格林 - 巴利综合症（GBS）和自身免疫性神经病）所导致的异常免疫介导损伤。</p>
<p>Annexon 的管线核心是 ANX005，这是一种针对 C1q 亚单位的人源化单克隆抗体，目前正在进行急性 GBS 和慢性神经退行性疾病的二期临床试验。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票超过 Annexon</li>
<li>海军催化剂点燃 Odysight 的增长引擎</li>
<li>AST SpaceMobile 因银河 Q1 业绩不佳暴跌：垂直整合能拯救这家 SpaceX 竞争对手吗？</li>
<li>Axon 在财报发布后大涨，但仍比高点下跌超过 50%</li>
<li>可能重新定义苹果夏季反弹的事件</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Annexon 吗？</h2>
<p>在考虑 Annexon 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Annexon 并不在名单上。</p>
<p>虽然 Annexon 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ANNX

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

<p>高盛集团将 Annexon（NASDAQ:ANNX）的评级上调至 “持有”。其他分析师的意见各不相同，Chardan Capital 维持 “买入” 评级，并设定 16 美元的目标价，而 Weiss Ratings 则给予 “卖出” 评级。Annexon 的股票开盘价为 5.44 美元，市值为 8.9129 亿美元。最近的内部交易包括首席财务官 Jennifer Lew 和执行副总裁 Michael Overdorf 的股份出售。机构投资者增加了持股比例，显示出日益增长的兴趣。随着未来几年的盈利预期上调，市场对 Annexon 的情绪积极，反映出对公司前景的信心增强</p>

<p>Annexon (NASDAQ:ANNX - Get Free Report) was upgraded by research analysts at The Goldman Sachs Group to a &#34;hold&#34; rating in a report issued on Tuesday,Zacks.com reports.</p>
<div class="lb-trans"><p>Annexon（纳斯达克股票代码：ANNX - 获取免费报告）在周二发布的报告中被高盛集团的研究分析师上调至 “持有” 评级，Zacks.com 报道。</p>
</div><p>A number of other equities analysts also recently issued reports on ANNX. Chardan Capital reiterated a &#34;buy&#34; rating and set a $16.00 price objective on shares of Annexon in a research note on Friday, March 20th. Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating on shares of Annexon in a report on Wednesday, January 14th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Annexon in a report on Monday, April 20th. Finally, Wall Street Zen raised shares of Annexon from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Annexon has an average rating of &#34;Hold&#34; and an average target price of $16.00.</p>
<div class="lb-trans"><p>其他一些股票分析师最近也对 ANNX 发布了报告。Chardan Capital 在 3 月 20 日的研究报告中重申了对 Annexon 的 “买入” 评级，并设定了 16.00 美元的目标价。Cantor Fitzgerald 在 1 月 14 日的报告中重申了对 Annexon 的 “增持” 评级。Weiss Ratings 在 4 月 20 日的报告中重申了对 Annexon 的 “卖出（d-）” 评级。最后，Wall Street Zen 在周六的报告中将 Annexon 的评级从 “卖出” 上调至 “持有”。四位分析师给予该股票 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Annexon 的平均评级为 “持有”，平均目标价为 16.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on Annexon</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Annexon 的最新研究报告</strong></p>
</div><h2>Annexon Price Performance</h2>
<div class="lb-trans"><h2>Annexon 价格表现</h2>
</div><p>Shares of ANNX stock opened at $5.44 on Tuesday. The company has a market capitalization of $891.29 million, a P/E ratio of -4.46 and a beta of 1.22. The company's 50-day simple moving average is $5.70 and its two-hundred day simple moving average is $5.14. Annexon has a one year low of $1.67 and a one year high of $7.18.</p>
<div class="lb-trans"><p>ANNX 股票在周二开盘价为 5.44 美元。该公司的市值为 8.9129 亿美元，市盈率为-4.46，贝塔值为 1.22。公司的 50 日简单移动平均线为 5.70 美元，200 日简单移动平均线为 5.14 美元。Annexon 的年低为 1.67 美元，年高为 7.18 美元。</p>
</div><p>Annexon (NASDAQ:ANNX - Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.07. On average, research analysts expect that Annexon will post -1.05 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Annexon（纳斯达克股票代码：ANNX - 获取免费报告）最近在 5 月 7 日发布了其财报。该公司报告季度每股收益（EPS）为-0.23 美元，超出分析师一致预期的-0.30 美元，超出幅度为 0.07 美元。研究分析师平均预计 Annexon 在当前财年将发布-1.05 美元的每股收益。</p>
</div><h2>Insider Activity at Annexon</h2>
<div class="lb-trans"><h2>Annexon 内部活动</h2>
</div><p>In other news, CFO Jennifer Lew sold 7,851 shares of Annexon stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.11, for a total value of $40,118.61. Following the sale, the chief financial officer owned 113,765 shares in the company, valued at $581,339.15. This trade represents a 6.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, EVP Michael Overdorf sold 6,225 shares of Annexon stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total transaction of $31,747.50. Following the completion of the sale, the executive vice president owned 124,464 shares in the company, valued at approximately $634,766.40. This trade represents a 4.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 32,513 shares of company stock valued at $165,973 in the last quarter. 12.67% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席财务官 Jennifer Lew 在 2 月 18 日的交易中出售了 7,851 股 Annexon 股票。这些股票以平均价格 5.11 美元出售，总价值为 40,118.61 美元。出售后，首席财务官持有公司 113,765 股股票，价值 581,339.15 美元。这笔交易代表其持股比例减少了 6.46%。该出售在向证券交易委员会提交的文件中披露，文件可通过此链接获取。此外，执行副总裁 Michael Overdorf 在 2 月 18 日的交易中出售了 6,225 股 Annexon 股票。这些股票以平均价格 5.10 美元出售，总交易额为 31,747.50 美元。出售完成后，该执行副总裁持有公司 124,464 股股票，价值约 634,766.40 美元。这笔交易代表其持股比例减少了 4.76%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在上个季度出售了 32,513 股公司股票，价值 165,973 美元。目前，内部人士持有该股票的比例为 12.67%。</p>
</div><h2>Hedge Funds Weigh In On Annexon</h2>
<div class="lb-trans"><h2>对 Annexon 的对冲基金看法</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the business. Rhenman &amp; Partners Asset Management AB boosted its position in Annexon by 78.9% during the third quarter. Rhenman &amp; Partners Asset Management AB now owns 823,000 shares of the company's stock worth $2,510,000 after acquiring an additional 363,000 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Annexon during the fourth quarter worth about $82,000. DNB Asset Management AS raised its stake in shares of Annexon by 40.0% in the 4th quarter. DNB Asset Management AS now owns 118,324 shares of the company's stock valued at $594,000 after acquiring an additional 33,801 shares during the period. CWM LLC raised its stake in shares of Annexon by 29.0% in the 4th quarter. CWM LLC now owns 30,297 shares of the company's stock valued at $152,000 after acquiring an additional 6,809 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Annexon by 65.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company's stock valued at $35,000 after acquiring an additional 2,785 shares during the period.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买入和卖出了该公司的股票。Rhenman &amp; Partners Asset Management AB 在第三季度将其在 Annexon 的持股比例提高了 78.9%。Rhenman &amp; Partners Asset Management AB 目前拥有 823,000 股公司股票，价值 2,510,000 美元，此前在上个季度增持了 363,000 股。Caitong International Asset Management Co. Ltd 在第四季度购买了 Annexon 的新头寸，价值约 82,000 美元。DNB Asset Management AS 在第四季度将其在 Annexon 的持股比例提高了 40.0%。DNB Asset Management AS 目前拥有 118,324 股公司股票，价值 594,000 美元，此前增持了 33,801 股。CWM LLC 在第四季度将其在 Annexon 的持股比例提高了 29.0%。CWM LLC 目前拥有 30,297 股公司股票，价值 152,000 美元，此前增持了 6,809 股。最后，Mirae Asset Global Investments Co. Ltd.在第四季度将其在 Annexon 的持股比例提高了 65.6%。Mirae Asset Global Investments Co. Ltd.目前拥有 7,033 股公司股票，价值 35,000 美元，此前增持了 2,785 股。</p>
</div><h2>Key Annexon News</h2>
<div class="lb-trans"><h2>Annexon 的关键新闻</h2>
</div><p>Here are the key news stories impacting Annexon this week:</p>
<div class="lb-trans"><p>以下是本周影响 Annexon 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: HC Wainwright lifted its earnings estimates for Annexon across multiple periods, including FY2026, FY2027, FY2028, and FY2029, signaling improved confidence in the company’s longer-term earnings trajectory.</li>
<li>Positive Sentiment: The firm also raised near-term quarterly EPS forecasts for Q2, Q3, and Q4 2026, which may help reinforce investor sentiment around Annexon’s operating outlook.</li>
<li>Neutral Sentiment: Separate market data showed short interest at zero shares, which does not appear to be a meaningful trading factor in the latest report.</li>
<li>Neutral Sentiment: An awareness-month press release tied to Guillain-Barré syndrome was also published, but it did not include a direct business update or clinical catalyst for Annexon. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：HC Wainwright 提高了对 Annexon 多个时期的收益预期，包括 2026 财年、2027 财年、2028 财年和 2029 财年，显示出对公司长期收益轨迹的信心增强。</li>
<li>积极情绪：该公司还提高了 2026 年第二、第三和第四季度的每股收益预测，这可能有助于增强投资者对 Annexon 运营前景的信心。</li>
<li>中性情绪：独立市场数据显示空头头寸为零股，这在最新报告中似乎并不是一个重要的交易因素。</li>
<li>中性情绪：与格林 - 巴利综合症相关的意识月新闻稿也已发布，但未包含对 Annexon 的直接业务更新或临床催化剂。文章标题</li>
</ul>
</div><h2>Annexon Company Profile</h2>
<div class="lb-trans"><h2>Annexon 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.</p>
<div class="lb-trans"><p>Annexon Inc 是一家临床阶段的生物技术公司，专注于针对神经退行性和神经免疫疾病患者的补体靶向疗法的发现和开发。该公司的研究平台以抑制 C1 复合物为核心，C1 复合物是经典补体途径的关键启动因子，涉及多种罕见且危及生命的疾病。通过选择性靶向上游补体激活，Annexon 旨在防止特征性疾病（如格林 - 巴利综合症（GBS）和自身免疫性神经病）所导致的异常免疫介导损伤。</p>
</div><p>At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.</p>
<div class="lb-trans"><p>Annexon 的管线核心是 ANX005，这是一种针对 C1q 亚单位的人源化单克隆抗体，目前正在进行急性 GBS 和慢性神经退行性疾病的二期临床试验。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Annexon</li>
<li>Navy Catalyst Ignites Odysight’s Growth Engine</li>
<li>AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?</li>
<li>Axon Surged After Earnings and Is Still Down Over 50% From Highs</li>
<li>The Event That Could Redefine Apple’s Summer Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Annexon</li>
<li>海军催化剂点燃 Odysight 的增长引擎</li>
<li>AST SpaceMobile 因银河 Q1 业绩不佳暴跌：垂直整合能拯救这家 SpaceX 竞争对手吗？</li>
<li>Axon 在财报发布后大涨，但仍比高点下跌超过 50%</li>
<li>可能重新定义苹果夏季反弹的事件</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ANNX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Annexon Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Annexon 吗？</h2>
</div><p>Before you consider Annexon, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Annexon 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Annexon 并不在名单上。</p>
</div><p>While Annexon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Annexon 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Annexon（NASDAQ:ANNX）被高盛集团升级至 “持有” 评级